Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

471

Enrollment

NIH

Sponsor class

Conditions

Peanut Allergy
Multi-food Allergy

Interventions

DRUG: Omalizumab
DRUG: Placebo for Omalizumab
DRUG: Multi-Allergen Oral Immunotherapy
DRUG: Placebo for Multi-Allergen Oral Immunotherapy
OTHER: Double-Blind Placebo-Controlled Food Challenge Based Treatment

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]